BioStem Technologies (OTCMKTS:BSEM) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of BioStem Technologies (OTCMKTS:BSEM) to a hold rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

BioStem Technologies Stock Down 1.2%

Shares of BSEM stock opened at $5.08 on Wednesday. The stock’s 50-day moving average price is $5.65 and its 200 day moving average price is $4.98. The stock has a market capitalization of $85.56 million, a PE ratio of 5.98 and a beta of -0.33. BioStem Technologies has a 52-week low of $3.09 and a 52-week high of $15.74.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.